Announced Tue, 27 May, 2025 · 14:50 IST
IOL Chemicals Q4 FY25 Earnings Call - Margin Guidance Above 15%
Mgmt Guided Margin ImprovementMgmt Evaded Key QuestionInvestor Communications View source PDFExplain this filing
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.6%1-day move
₹87.25
prior close
₹88.29
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+0.2+0.2+0.3+0.6+3.1+0.5+3.0+0.7-0.3-1.1+11.5+5.9+4.0
Up moveDown movePending
AI summary
Q4 FY25 revenue grew 4.7% YoY to INR 528 cr; full year INR 2,079 cr. Q4 EBITDA margin up 141 bps to 12.7%; PAT INR 31.6 cr, up 12%. FY25 EBITDA INR 225 cr at 11% margin. Net debt to equity at 0.09. Guided FY26 EBITDA margin above 15% and 10-15% revenue growth. Capex plan INR 150-200 cr. Paracetamol at 10,800 MTPA. Exports 27%, target 40-45% in 2 years. China Ibuprofen approval, Clopidogrel capacity up 33%.
Likely market impact
Positive: guided FY26 EBITDA margin above 15% beats FY25's 11%. Low debt (0.09) supports INR 150-200 cr capex. Risk: U.S. FDA inspection pending.